Publications by authors named "Akla S"
Article Synopsis
- A nationwide survey in France asked breast cancer survivors about their thoughts on personalizing endocrine therapy (ET) to make it better for patients.
- Most participants agreed that schedules and pill types should be customized, but many didn't have a strong opinion about how the medicine looked.
- Many survivors wanted more information and tools, like a mobile app, to help manage side effects and understand ET's effects on their daily lives.
SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA-mutant, hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC) patients. We report here real-life data of patients prospectively registered in the French alpelisib early access program (EAP) opened to PIK3CA-mutant HR+/HER2- ABC patients treated with alpelisib and fulvestrant. Primary endpoint was PFS by local investigators using RECIST1.
View Article and Find Full Text PDF